drugset / Trial / NCT06736392

Efficacy of Dexmedetomidine As an Adjuvant to Bupivacaine in Pericapsular Nerve Group Block in Hip Replacement Surgeries

NCT06736392

Phase 2 Not yet recruiting 60 enrolled Assiut University
RandomizedParallel-groupOpen-labelSupportive care

Summary

Our aim will be to investigate the efficacy of dexmedetomidine as an adjuvant to bupivacaine in ultrasound guided pericapsular nerve group (PENG) block for postoperative analgesia in hip replacement surgeries. * Our primary outcome of the study: total amount of postoperative morphine consumption in the first 24h postoperative. * Our secondary outcome of the study: postoperative analgesia assessed by pain score (by Visual Analog Scale)

Timeline

Start
2025-03-01
Primary completion
2026-08
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 1.5 ug/kg
Comparator Bupivacaine Other / unclassified 0.25 %
Comparator Bupivacaine Other / unclassified 20 ml

Indications

No indication recorded.